We are live on ! Find out more
PLXP

PLx Pharma Inc. Common Stock
PLXP

Delisted

PLXP was delisted on the 12th of April, 2023.

Back to rankings

17 hedge funds and large institutions have $11.3M invested in PLx Pharma Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

249% more capital invested

Capital invested by funds: $3.25M → $11.3M (+$8.09M)

21% more funds holding

Funds holding: 14 → 17 (+3)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Holders
17
Holders Change
+3
Holders Change %
+21.43%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
3
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HWA
Heritage Way Advisors
Illinois
+$122K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$84.6K
3
Renaissance Technologies
Renaissance Technologies
New York
+$72.9K
4
Northern Trust
Northern Trust
Illinois
+$54.3K
5
Bank of America
Bank of America
North Carolina
+$9.78K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$46.9K
2
Goldman Sachs
Goldman Sachs
New York
-$30K
3
Millennium Management
Millennium Management
New York
-$24.1K
4
BlackRock
BlackRock
New York
-$2K
Name Holding Trade Value Shares
Change 		Change in
Stake
PWAM
1
Park West Asset Management
California
$7.73M – – –
HIIFS
2
Harel Insurance Investments & Financial Services
Israel
$1.31M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$592K +$84.6K +17,300 +18%
Brown Advisory
4
Brown Advisory
Maryland
$392K – – –
UOTTAIMCU
5
University of Texas/Texas AM Investment Management Co (UTIMCO)
Texas
$329K – – –
Renaissance Technologies
6
Renaissance Technologies
New York
$308K +$72.9K +14,900 +34%
Millennium Management
7
Millennium Management
New York
$274K -$24.1K -4,938 -9%
HWA
8
Heritage Way Advisors
Illinois
$131K +$122K +25,000 New
Fayez Sarofim & Co
9
Fayez Sarofim & Co
Texas
$72K – – –
Northern Trust
10
Northern Trust
Illinois
$59K +$54.3K +11,103 New
CWM
11
Cranbrook Wealth Management
Michigan
$39K – – –
Wells Fargo
12
Wells Fargo
California
$32K – – –
BlackRock
13
BlackRock
New York
$21K -$2K -410 -9%
UBS Group
14
UBS Group
Switzerland
$16K -$46.9K -9,595 -77%
Bank of America
15
Bank of America
North Carolina
$11K +$9.78K +2,000 New
Deutsche Bank
16
Deutsche Bank
Germany
$6K +$5.87K +1,200 New
Morgan Stanley
17
Morgan Stanley
New York
$1K – – –
Goldman Sachs
18
Goldman Sachs
New York
– -$30K -19,671 Closed

PLXP Hedge Fund Activity: Q1 2019 in Review

17 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in PLx Pharma Inc. Common Stock (PLXP) for Q1 2019, worth a combined $11.3M — up 249% from $3.25M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new PLXP positions and 1 closed out — a net gain of 3 holders — while 2 added to existing stakes and 3 trimmed.

The largest buyer was Heritage Way Advisors, opening a new position worth an estimated $122K. The largest seller was UBS Group, cutting an estimated $46.9K.

  • 17 institutional investors held PLx Pharma Inc. Common Stock (PLXP) as of Q1 2019, up from 14 in Q4 2018.
  • Funds reported $11.3M of PLx Pharma Inc. Common Stock stock for Q1 2019, up 249% quarter-over-quarter.
  • 4 funds opened new PLx Pharma Inc. Common Stock positions in Q1 2019 and 1 closed out, a net change of +3 holders.
  • The largest PLx Pharma Inc. Common Stock buyer in Q1 2019 was Heritage Way Advisors, an estimated $122K added.
  • The largest PLx Pharma Inc. Common Stock seller in Q1 2019 was UBS Group, an estimated $46.9K sold.

Based on aggregated 13F filings for Q1 2019.